

EuroSIDA Newsletter

November 2016

ANNOUNCEMENTS

Dear EuroSIDA Study Investigators,

The EuroSIDA Coordinating Office sends you many pre-winter greetings and as always, thank you for your continued excellent work and important contributions to the EuroSIDA study.

Glasgow 2016

We were very happy to see more than 40 EuroSIDA investigators at the Glasgow investigator meeting. We hope you found the meeting informative!

We touched upon the past year in EuroSIDA and current study status as well as the new data collection structure, EuroSIDA scientific interest groups and the RESPOND consortium. More information may be found in the minutes from the investigator meeting, which will be circulated to all investigators. We are excited to be in a process of shaping a competitive and clinically relevant research agenda for the coming years, building on EuroSIDA's excellent research collaboration and success through 20 years.

Dates will be announced within a few weeks for anyone wishing to participate in teleconferences which will shape the different scientific working groups. All teleconferences will also be announced on the website <http://www.chip.dk/Studies/EuroSIDA/Meetings>.



Glasgow presentations

EuroSIDA was well represented at Glasgow with two thistle poster presentations and one oral presentation. Please find them [HERE](#)

If you missed Kamilla Laut's oral presentation at Glasgow here is

Deadlines:

Follow up 44: 1 December 2016

HCV Follow Up 44: 1 December 2016

Enrolment: 31 December 2016

All other forms will be kept open and may be filled in continuously

Integrase Inhibitor hypersensitivity (HSR) forms:

Please remember to **complete the retrospective integrase inhibitor hypersensitivity forms** if a reminder was sent to you in the DS44 package on 1 October 2016, as soon as possible. The deadline for completing these forms was 1st November 2016.

Reimbursement

All reimbursements will take place in December this year.

EuroSIDA study documents

Please remember that you can find relevant study documents [HERE](#). The study documents have been updated, and documents relating to dataset 44 have been combined into *Instructions for EuroSIDA data collection ds44 (Autumn 2016)*.

Change in staff

Please remember to update the EuroSIDA coordinating centre if there are changes to staff. This allows information, newsletters etc. to be sent to the right person and also allows us to keep the study group updated and thus award co-authorships to the right people. Furthermore, if staff no longer works at

your chance to see it again! Please click [THIS](#) link to view the webcast.

Big thanks to all of you for your contribution towards our continued scientific success!

HCV Treatment forms

The new version of the HCV Treatment Form is shorter and should be easier to complete than the previous version. All biochemistry and some other additional information have been removed, and we no longer ask for the HCV-RNA assay. However, **we now collect HCV-RNA up to 12 weeks after end of treatment.** If possible, we recommend that the first data is entered once a patient starts HCV treatment, but the status of the form should be "incomplete" until the last HCV-RNA has been entered.

When creating a new HCV Treatment Form for patients where treatment was started prior to October 1 2016, please make sure that the same information has not already been reported in the former version or the form.

For treatment forms created prior to October 1st 2016, many forms are still incomplete, or queries have not been addressed. Please complete these forms as soon as possible.

Plasma samples

Because of the recent changes in data collection, we have received many questions regarding the collection of plasma samples. Please be advised that the following still applies:

Plasma sample should if possible, be collected twice a year for all patients participating in EuroSIDA. This can occur together with any scheduled visit to the clinic.

Please store the samples locally and keep a list of samples collected/stored available. Samples should be sent annually or when a volume of samples of approx. 240 vials is ready for shipment. If plasma is stored at -20° Celsius these should be shipped every 6 months. When ready to ship samples from a site to CHIP, please send an email to annette.hauberg.fischer@regionh.dk. Please find more information [HERE](#)

EuroSIDA cohort 10

Enrolment will end on 31 December 2016, so if you still have patients to include, please do so as soon as possible.

PUBLICATIONS

Total number of publications in 2016: 19

Publications since last newsletter September 2016: 3

Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C

your site, we need to remove their REDCap access.

Contact

Please always feel free to contact the EuroSIDA coordinating centre at eurosida.rigshospitalet@regionh.dk. No question is too small or too big, we are happy to assist in all matters!



Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. Gærde LI, Shepherd L Jablonowska E, Lazzarin A, Rougemont M, Darling K, Battegay M, Braun D, Martel-Laferriere V, Lundgren JD, Rockstroh JK, Gill J, Rauch A, Mocroft A, Klein MB, Peters L.
Clin Infect Dis. 2016 Sep 15;63(6):821-9.

Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, d'Arminio Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne J; Antiretroviral Therapy Cohort Collaboration (ART-CC).
PLoS One. 2016 Aug 15;11(8):e0160460.

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: a prospective cohort study. JM Llibre, A Cozzi-Lepri, C Pedersen, M Ristola, M Losso, A Mocroft, V Mitsura, K Falconer, F Maltez, M Beniowski, V Vullo, G Hassoun, E Kuzovatova, J Szlavik, A Kuznetsova, H-J Stellbrink, C Duivier, S Edwards, K Laut, R Paredes for the EuroSIDA Study Group.
Medicine: Volume 95(40), October 2016, p e5020.

All publications may be found [HERE](#)

Thank you for a continuous rewarding and successful collaboration!

EuroSIDA Coordinating Centre. Rigshospitalet, CHIP, Department of Infectious Diseases, Section 2100, Finsencentret. Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.

Tel: +45 35 45 57 57. Fax: +45 35 45 57 58. E-mail: EuroSIDA.rigshospitalet@regionh.dk

Web: www.regionh.dk www.chip.dk